Program
eptinezumab
Also written as “Eptinezumab”, “ALD403” and “ALD403 (Eptinezumab)”.
Its studies are mostly in Migraine Disorders · Cluster Headache, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 223 open or running | phase 4since Feb 23, 2022 | Apr 16, 2012 | Mar 26, 2027phase 3 · NCT04965675 |
| Dr George Medvedev | 11 open or running | phase 3since May 16, 2024 | May 16, 2024 | Mar 2028phase 3 · NCT06428838 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Apr 16, 2012.
- Aug 28, 2020Phase 1 study in Migraine DisordersH. Lundbeck · NCT04537429 · 28 enrolled · United States
- Dec 24, 2020Phase 3 study in Cluster HeadacheH. Lundbeck · NCT04688775 · 231 enrolled · United States, Belgium, Czechia and more
- Feb 23, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT04772742 · 193 enrolled · China, Georgia, Korea, Republic of and more
- Jun 4, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT04921384 · 981 enrolled · China, Georgia, Japan and more
- Jul 7, 2021Phase 3 study in Chronic Migraine in ChildrenH. Lundbeck · NCT04965675 · 285 planned · United States, Argentina, Canada and more
- Sep 7, 2021Phase 1 study in HealthyH. Lundbeck · NCT05045781 · 20 enrolled · China
- Sep 22, 20212 phase 3 studiesH. Lundbeck · NCT05064397, NCT05064371
- Dec 7, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT05164172 · 600 planned · United States, Argentina, Canada and more
- Feb 23, 2022Phase 4 study in Migraine DisordersH. Lundbeck · NCT05284019 · 32 enrolled · United States
- Jul 6, 2022Phase 4 study in Migraine DisordersH. Lundbeck · NCT05452239 · 608 enrolled · United States, Australia, Denmark and more
- May 31, 2023Phase 3 study in Episodic MigraineH. Lundbeck · NCT05897320 · 315 planned · United States, Argentina, Canada and more
- May 16, 2024Dr George Medvedev's first study: phase 3 study in Migraine DisordersNew to Dr George MedvedevDr George Medvedev · NCT06428838 · 102 planned · Canada
- Nov 20, 2024Phase 4 study in Migraine DisordersH. Lundbeck · NCT06701526 · 164 enrolled · United States
- Oct 16, 2026Primary completion moved from 2026-09-05 to 2027-03-26Date moved laterphase 3 · +7 months · NCT04965675
Ahead
- Mar 26, 2027Primary completion: phase 3 study in Chronic Migraine in ChildrenH. Lundbeck · NCT04965675
- Jul 6, 2027Primary completion: phase 3 study in Episodic MigraineH. Lundbeck · NCT05897320
- Mar 2028Primary completion: phase 3 study in Migraine DisordersDr George Medvedev · NCT06428838
- Apr 30, 2028Primary completion: phase 3 study in Migraine DisordersH. Lundbeck · NCT05164172
TargetBeta
“Calcitonin gene-related peptide inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06701526Migraine Disorders · United States | 4 | Completed | H. Lundbeck | Sep 2, 2026 | 164 |
| NCT06428838Migraine Disorders · Canada | 3 | By invitation | Dr George Medvedev | Mar 2028 | 102 |
| NCT05897320Episodic Migraine · United States, Argentina, Canada and more | 3 | Recruiting | H. Lundbeck | Jul 6, 2027 | 315 |
| NCT05452239Migraine Disorders · United States, Australia, Denmark and more | 4 | Completed | H. Lundbeck | Oct 22, 2024 | 608 |
| NCT05284019Migraine Disorders · United States | 4 | Terminated | H. Lundbeck | Feb 17, 2023 | 32 |
| NCT05164172Migraine Disorders · United States, Argentina, Canada and more | 3 | Recruiting | H. Lundbeck | Apr 30, 2028 | 600 |
| NCT05064397Cluster Headache · United States, Denmark, Finland and more | 3 | Completed | H. Lundbeck | Jun 29, 2023 | 131 |
| NCT05064371Migraine Disorders · Japan | 3 | Completed | H. Lundbeck | Jun 8, 2024 | 160 |
| NCT05045781Healthy · China | 1 | Completed | H. Lundbeck | Jul 20, 2021 | 20 |
| NCT04965675Chronic Migraine in Children · United States, Argentina, Canada and more | 3 | Recruiting | H. Lundbeck | Mar 26, 2027 | 285 |
| NCT04921384Migraine Disorders · China, Georgia, Japan and more | 3 | Completed | H. Lundbeck | Oct 1, 2024 | 981 |
| NCT04772742Migraine Disorders · China, Georgia, Korea, Republic of and more | 3 | Completed | H. Lundbeck | May 23, 2022 | 193 |
| NCT04688775Cluster Headache · United States, Belgium, Czechia and more | 3 | Completed | H. Lundbeck | Jun 14, 2023 | 231 |
| NCT04537429Migraine Disorders · United States | 1 | Completed | H. Lundbeck | Oct 20, 2022 | 28 |
| NCT04418765Migraine Disorders · United States, Belgium, Bulgaria and more | 3 | Completed | H. Lundbeck | Jul 15, 2021 | 892 |
| NCT04336449Healthy · Japan | 1 | Completed | H. Lundbeck | Aug 13, 2020 | 18 |
| NCT04152083Migraine Disorders · United States, Georgia | 3 | Completed | H. Lundbeck | Jul 8, 2020 | 485 |
| NCT02985398Migraine Disorders · United States | 3 | Completed | H. Lundbeck | Apr 2018 | 128 |
| NCT02974153Migraine Disorders · United States, Belgium, Czechia and more | 3 | Completed | H. Lundbeck | Nov 2017 | 1,121 |
| NCT02559895Migraine Disorders · United States, Georgia | 3 | Completed | H. Lundbeck | Feb 2017 | 898 |
| NCT02275117Migraine Disorders · United States, Australia, Georgia and more | 2 | Completed | H. Lundbeck | Mar 2016 | 665 |
| NCT01772524Migraine Disorders · United States | 1 | Completed | H. Lundbeck | Dec 2013 | 163 |
| NCT01579383Migraine Disorders · Australia | 1 | Completed | H. Lundbeck | Dec 2012 | 104 |
How it is read
Names in the registry
- “Eptinezumab”, 17 entries
- “ALD403”, 5 entries
- “ALD403 (Eptinezumab)”, 2 entries
Conditions, from the studies’ own filings
- Migraine Disorders, 19 studies
- Cluster Headache, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.